Business Wire

CA-LEGENDARY-PICTURES

Share
Director Adam Wingard Returns as Warner Bros. Pictures and Legendary Pictures Explore the Next Chapter in the Massive Monsterverse Franchise

Coming off the global success of 2021’s “Godzilla vs Kong” cameras are now rolling on the latest entry in Warner Bros. Pictures’ and Legendary Pictures’ cinematic Monsterverse. This latest entry follows up the explosive showdown of Godzilla vs. Kong with an all-new cinematic adventure, pitting the almighty Kong and the fearsome Godzilla against a colossal undiscovered threat hidden within our world, challenging their very existence – and our own. The epic new film will delve further into the histories of these Titans, their origins and the mysteries of Skull Island and beyond, while uncovering the mythic battle that helped forge these extraordinary beings and tied them to humankind forever.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005274/en/

The film, which recently began principal photography, is again being helmed by director Adam Wingard (“You’re Next” “The Guest”) and stars returning cast members Rebecca Hall (“The Night House” “Resurrection”), Brian Tyree Henry (“Bullet Train” “Atlanta”), and Kaylee Hottle (“Godzilla vs. Kong”), who are now joined by newcomers Dan Stevens (“Gaslit” “Legion” “Beauty and the Beast”), Fala Chen (“Irma Vep” “Shang Chi and the Legend of the Ten Rings”), Alex Ferns (“The Batman” “Wrath of Man” “Chernobyl”) and Rachel House (“Hunt for the Wilderpeople” “Thor: Ragnarok” “Foundation”).

Wingard is directing the currently untitled project from a script by Terry Rossio (“Godzilla vs. Kong” the “Pirates of the Caribbean” series), Jeremy Slater (“Moon Knight”) and Simon Barrett (“You’re Next”). The film is being produced by Mary Parent, Alex Garcia, Eric Mcleod, Brian Rogers, Thomas Tull, and Jon Jashni, with executive producers Josh Grode, Adam Wingard, Jay Ashenfelter, Jen Conroy, Kenji Okuhira and Yoshimitsu Banno.

Once again, Wingard is collaborating with director of photography Ben Seresin (“Godzilla vs. Kong” “World War Z”), production designer Tom Hammock (“Godzilla vs. Kong” “X” “The Guest”), editor Josh Schaeffer (“Godzilla vs. Kong” “Molly’s Game”), and composer Tom Holkenborg (“Godzilla vs. Kong” “Mad Max: Fury Road”), who are now joined by costume designer Emily Seresin (“The Invisible Man” “Top of the Lake”), makeup artist Sabrina Wilson (“Captain Marvel” “The Suicide Squad” “The Book of Bobba Fett”), hairstylist Gloria Pasqua Casny (“The Tomorrow War” “Ford vs Ferrari”), and VFX supervisor Alessandro Ongaro (“The Adam Project” “Ghostbusters: Afterlife”).

The film is being shot on location in Queensland, Australia and is slated for a March 15, 2024, worldwide release from Warner Bros. Pictures except in Japan where it will be distributed by Toho Co., Ltd and in mainland China where it will be distributed by Legendary East.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye